IBD Monitor: Romanian National Mobile Application for Inflammatory Bowel Disease Personalized Treatment and Monitoring.

inflammatory bowel disease mobile application national registry patient support

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
28 May 2022
Historique:
received: 11 05 2022
revised: 26 05 2022
accepted: 26 05 2022
entrez: 24 6 2022
pubmed: 25 6 2022
medline: 25 6 2022
Statut: epublish

Résumé

In the last 30 years, we have seen an increase in the incidence of inflammatory bowel disease (IBD). Most cases are diagnosed in the 2nd and 3rd decades of life, a population group that is most familiar with the latest innovations in technology. Patients want to obtain more information about their disease and have complete control over the pathology, while reducing physical meetings with their doctor. Starting from these ideas, the present study aimed to develop a mobile application (app) to support IBD patients on symptoms/events reporting and on treatment administration monitoring. A multidisciplinary team was created to document and develop the app requirements and design its functionality. The app was beta-tested by several IBD patients. Their feedback was used to further refine the app. We developed connected apps for both smartphones and smartwatches, with dedicated sections for event reporting and medication administration reminders/reporting. The development of apps dedicated to IBD patients is still in early progress. By creating this app, we aim to improve the evolution and compliance of IBD patients and to obtain new information that will have a beneficial impact on the management of these patients and open the door for personalized medicine.

Sections du résumé

BACKGROUND BACKGROUND
In the last 30 years, we have seen an increase in the incidence of inflammatory bowel disease (IBD). Most cases are diagnosed in the 2nd and 3rd decades of life, a population group that is most familiar with the latest innovations in technology. Patients want to obtain more information about their disease and have complete control over the pathology, while reducing physical meetings with their doctor. Starting from these ideas, the present study aimed to develop a mobile application (app) to support IBD patients on symptoms/events reporting and on treatment administration monitoring.
METHODS METHODS
A multidisciplinary team was created to document and develop the app requirements and design its functionality. The app was beta-tested by several IBD patients. Their feedback was used to further refine the app.
RESULTS RESULTS
We developed connected apps for both smartphones and smartwatches, with dedicated sections for event reporting and medication administration reminders/reporting.
CONCLUSIONS CONCLUSIONS
The development of apps dedicated to IBD patients is still in early progress. By creating this app, we aim to improve the evolution and compliance of IBD patients and to obtain new information that will have a beneficial impact on the management of these patients and open the door for personalized medicine.

Identifiants

pubmed: 35741155
pii: diagnostics12061345
doi: 10.3390/diagnostics12061345
pmc: PMC9221845
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Patient Prefer Adherence. 2012;6:127-35
pubmed: 22379363
Am J Gastroenterol. 2007 Sep;102(9):2070-7
pubmed: 17511753
Inflamm Bowel Dis. 2018 Jun 8;24(7):1453-1459
pubmed: 29868764
Inflamm Bowel Dis. 2007 Oct;13(10):1266-70
pubmed: 17567877
N Engl J Med. 2007 Jun 14;356(24):2451-4
pubmed: 17568026
JMIR Res Protoc. 2015 Feb 18;4(1):e23
pubmed: 25693610
JAMA. 2004 Jul 28;292(4):435-41
pubmed: 15280341
J Clin Oncol. 2001 Mar 15;19(6):1676-87
pubmed: 11250997
BMC Med Inform Decis Mak. 2013 Nov 16;13:127
pubmed: 24238397
Gastroenterol Hepatol (N Y). 2018 Sep;14(9):529-531
pubmed: 30364254
JMIR Mhealth Uhealth. 2016 Feb 01;4(1):e13
pubmed: 26831935
Curr Health Sci J. 2020 Apr-Jun;46(2):103-110
pubmed: 32874680
Lancet. 2017 Sep 2;390(10098):959-968
pubmed: 28716313
J Am Pharm Assoc (2003). 2013 Mar-Apr;53(2):172-81
pubmed: 23571625
Diabetes Care. 2011 Mar;34(3):533-9
pubmed: 21266648
Inflamm Bowel Dis. 2013 Jun;19(7):1534-45
pubmed: 23635715
Inflamm Bowel Dis. 2008 Oct;14 Suppl 2:S4-5
pubmed: 18816745
Gut. 2004 Oct;53(10):1479-84
pubmed: 15361498
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30
pubmed: 31648971
Patient Prefer Adherence. 2014 Jan 07;8:63-72
pubmed: 24470755

Auteurs

Carmen-Nicoleta Oancea (CN)

Department of Analytical Chemistry, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.

Răzvan-Cristian Statie (RC)

Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy of Craiova, 200638 Craiova, Romania.
Department of Gastroenterology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.

Dan-Ionuț Gheonea (DI)

Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy of Craiova, 200638 Craiova, Romania.
Department of Gastroenterology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.

Tudorel Ciurea (T)

Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy of Craiova, 200638 Craiova, Romania.
Department of Gastroenterology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.

Mircea-Sebastian Șerbănescu (MS)

Department of Medical Informatics and Biostatistics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.

Costin-Teodor Streba (CT)

Department of Gastroenterology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Department of Pulmonology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.

Classifications MeSH